Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00280631

Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

Phase 1-2a Dose-Ranging Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

Sponsor: Telik

Conditions Myelodysplastic Syndrome (MDS)

Updated 6 times since 2017 Last updated: May 30, 2012 Started: Feb 28, 2006 Primary completion: Mar 31, 2008 Completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00280631, this PHASE1/PHASE2 trial focuses on Myelodysplastic Syndrome (MDS) and remains completed. Sponsored by Telik, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Telik

Data source: Telik

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Maywood, United States
• Worcester, United States